HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cholinergic approaches to the treatment of progressive supranuclear palsy.

Abstract
In spite of the severe loss of cholinergic neurons in the brains of patients with progressive supranuclear palsy (PSP), marginal or null benefits are seen in clinical trials after the administration of physostigmine, a cholinesterase inhibitor, or RS-86, a cholinergic agonist. The possible role of cholinergic therapy in PSP is reevaluated.
AuthorsI Litvan
JournalJournal of neural transmission. Supplementum (J Neural Transm Suppl) Vol. 42 Pg. 275-81 ( 1994) ISSN: 0303-6995 [Print] Austria
PMID7964692 (Publication Type: Journal Article, Review)
Chemical References
  • Cholinergic Agonists
  • Succinimides
  • 2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione
  • Physostigmine
Topics
  • Cholinergic Agonists (therapeutic use)
  • Humans
  • Physostigmine (therapeutic use)
  • Succinimides (therapeutic use)
  • Supranuclear Palsy, Progressive (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: